Platinum-based chemotherapy remains a cornerstone in the treatment of platinum-sensitive ovarian cancer (PSOC) due to its demonstrated efficacy in prolonging progression-free survival (PFS).1-3 Retreatment with platinum agents, especially in patients who have been exposed to poly ADP-ribose polymerase inhibitors (PARPi) presents challenges with respect to both efficacy and toxicity. Recently, novel targeted therapies, including antibody-drug conjugates (ADCs), have been examined in the platinum-resistant ovarian cancer (PROC) space.